Sentence examples for fold survival from inspiring English sources

Transplant patients consistently have a 4 fold survival advantage compared with dialysis patients [ 6, 11].

A much smaller 2 to 3-fold survival phenotype was observed at 37°C and with EHEC (Figure 11).

This construct conferred a 3- to 4-fold survival advantage on peripheral Mst1−/− CD8+ T cells, examined 4 weeks after transplantation, compared to those transplanted with cells transduced with a control pMSCV-IRES-GFP (Mig) virus (Figure 5C; p = 0.014).

Indeed, multivariate analyses indicated that the combination of low p53 immunostaining scores and young age rendered an approximate two-fold survival advantage.

We observed a significant 2-fold survival in OL cultures treated with 1.0  μg/ml ephrinB3 as compared with vehicle, where ephrinB3/staurosporine-treated OLs did not differ significantly from controls (P>0.05).

Multivariate analyses indicate low p53 immunostaining scores and young age to render an approximate two-fold survival advantage; however, low-grade histology per se yielded an approximate nine-fold advantage (Table 3).

Such clinical chronopharmacologic development of gemcitabine-platinum combination is warranted in view of both the limited efficacy of current treatment regimens in advanced lung cancer and the three-fold survival benefit achieved here by the optimal circadian schedule as compared to concurrent dosing of both agents in the experimental model.

L. brevis cells with overexpressed CAT showed 685-fold and 823-fold higher survival when exposed to 30 mmol/L of H2O2 and long-term aerated stress (after 72 h), respectively, than that of the wild type cells.

Survival of the bacteria was evaluated in the presence of either 1 mM H2O2 or NaNO2 at pH 5. Curcumin treated S. Typhimurium showed 2 3 fold higher survival in the presence of H2O2 and NO. as compared to untreated S. Typhimurium (Figure 4A & B respectively).

Hoechst toxicity increased with increasing exposure times resulting in 25- to 45-fold reduced survival in irradiated cells and 4- to 5-fold reduced survival in untreated cells.

KP1339 monotherapy led to a 2.4-fold increase in life span and, thus, was superior to sorafenib, which induced a 1.9-fold prolonged survival.